C-Met Modulators and Methods of Use
The present invention provides compounds, which have activity for modulating protein kinase enzymatic activity and are potentially useful for modulating cellular activities such as, e.g., proliferation, differentiation, programmed cell death, migration and chemoinvasion. The present invention also provides compositions containing such compounds, and methods for producing and using such compounds and compositions.
1 - 43 . (canceled)
44 . A compound, which is
Name
Structure
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N′-[2-(4-fluorophenyl)ethyl]ethanediamide
45 - 52 . (canceled)
53 . A pharmaceutical composition comprising a compound according to claim 44 and a pharmaceutically acceptable carrier.
54 . A metabolite of the compound according to claim 44 .
55 . A method of modulating the in vivo activity of a kinase, the method comprising administering to a subject an effective amount of the compound according to claim 44 .
56 . The method according to claim 55 , wherein modulating the in vivo activity of the kinase comprises inhibition of said kinase.
57 . The method according to claim 55 , wherein the kinase is at least one of c-Met, KDR, c-Kit, flt-3, and flt-4.
58 . The method according to claim 57 , wherein the kinase is c-Met.
59 . A method of treating diseases or disorders associated with uncontrolled, abnormal, and/or unwanted cellular activities, the method comprising administering, to a mammal in need thereof, a therapeutically effective amount of the compound as described in claim 44 or a pharmaceutical composition comprising a compound according to claim 44 and a pharmaceutically acceptable carrier.
60 . A method of screening for a modulator of a kinase, said kinase selected from c-Met, KDR, c-Kit, fit-3, and flt-4, the method comprising combining the compound according to claim 44 and at least one candidate agent and determining the effect of the candidate agent on the activity of said kinase.
61 . A method of inhibiting proliferative activity in a cell, the method comprising administering an effective amount of the compound according to claim 44 to a cell or a plurality of cells.
62 . The method of claim 55 , wherein the compound is administered in combination with a pharmaceutically acceptable carrier.
63 . The method of claim 61 , wherein the compound is administered in combination with a pharmaceutically acceptable carrier.